MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm14082541

Медицинская библиотека · Journal of clinical medicine · 2025

Recurrence-Free Survival in Composite Hemangioendothelioma: A Case Study and Updated Systematic Review.

Reljic Milorad, Rajovic Nina, Rakocevic Jelena, Tadic Boris, Markovic Ksenija, Ostojic Slavenko, Raspopovic Milos, Toskovic Borislav, Masic Jelena Vladicic, Masic Srdjan, Milic Natasa, Knezevic Djordje

СтатьяОбзорПеревод в очереди

Аннотация

Background/

Objectives

Composite hemangioendothelioma (CHE) is a rare vascular endothelial tumor with borderline malignancy. This study presents a case of CHE and an updated systematic review of previously reported cases, providing insights into recurrence patterns and survival outcomes.

Methods

A comprehensive electronic search was conducted across PubMed, Scopus, the Cochrane Library, and Web of Science up to 31 December 2024, to identify eligible case reports. Kaplan-Meier curves were used to estimate event-free survival.

Results

We report a 61-year-old man with a splenic lesion associated with weight loss and abdominal pain persisting for 1 year. Intraoperative findings revealed an enlarged spleen and multiple hepatic deposits. Splenectomy and liver biopsy revealed a well-demarcated, nodular tumor measuring 160 × 145 × 100 mm, with histological and immunohistochemical findings consistent with CHE, complicated by hepatic metastasis. Of 405 potentially eligible studies, 59 were included in the review, covering cases from 2000 to 2024, with a peak in 2020 and 2023. The median age of patients was 42 years, with the most common tumor sites being the lower extremities (30.48%), followed by the face, head, and neck (20.95%), and upper extremities (18.1%). Surgical intervention was the most common treatment (60.95%). Recurrence-free survival was observed in 42.86% of cases, while 15.24% experienced recurrence with or without metastasis. Two patients (1.90%) died from the disease. The median recurrence-free survival was 48 months (95% CI: 7.3-88.7).

Conclusions

CHE exhibits significant morphological variation and can mimic other vascular tumors. Accurate diagnosis is crucial for proper prognosis and avoiding overtreatment due to misdiagnosis as more aggressive neoplasms. Patients with high-risk CHE should undergo closer surveillance to ensure timely detection of progression.

Для цитирования: Reljic Milorad, Rajovic Nina, Rakocevic Jelena, Tadic Boris, Markovic Ksenija, Ostojic Slavenko, Raspopovic Milos, Toskovic Borislav, Masic Jelena Vladicic, Masic Srdjan, Milic Natasa, Knezevic Djordje. Recurrence-Free Survival in Composite Hemangioendothelioma: A Case Study and Updated Systematic Review.. Journal of clinical medicine. 2025. DOI: 10.3390/jcm14082541.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.